656 related articles for article (PubMed ID: 17532492)
1. The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities.
Yun CH; Kim KH; Kim DH; Jung HC; Pan JG
Trends Biotechnol; 2007 Jul; 25(7):289-98. PubMed ID: 17532492
[TBL] [Abstract][Full Text] [Related]
2. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium.
Gustafsson MC; Roitel O; Marshall KR; Noble MA; Chapman SK; Pessegueiro A; Fulco AJ; Cheesman MR; von Wachenfeldt C; Munro AW
Biochemistry; 2004 May; 43(18):5474-87. PubMed ID: 15122913
[TBL] [Abstract][Full Text] [Related]
3. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP
Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858
[TBL] [Abstract][Full Text] [Related]
4. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450.
Otey CR; Bandara G; Lalonde J; Takahashi K; Arnold FH
Biotechnol Bioeng; 2006 Feb; 93(3):494-9. PubMed ID: 16224788
[TBL] [Abstract][Full Text] [Related]
5. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
[TBL] [Abstract][Full Text] [Related]
6. Protein engineering of the cytochrome P450 monooxygenase from Bacillus megaterium.
Urlacher VB; Schmid RD
Methods Enzymol; 2004; 388():208-24. PubMed ID: 15289074
[No Abstract] [Full Text] [Related]
7. Construction of a thermostable cytochrome P450 chimera derived from self-sufficient mesophilic parents.
Eiben S; Bartelmäs H; Urlacher VB
Appl Microbiol Biotechnol; 2007 Jul; 75(5):1055-61. PubMed ID: 17468867
[TBL] [Abstract][Full Text] [Related]
8. Laboratory evolution of P450 BM3 for mediated electron transfer yielding an activity-improved and reductase-independent variant.
Nazor J; Dannenmann S; Adjei RO; Fordjour YB; Ghampson IT; Blanusa M; Roccatano D; Schwaneberg U
Protein Eng Des Sel; 2008 Jan; 21(1):29-35. PubMed ID: 18093991
[TBL] [Abstract][Full Text] [Related]
9. The dimeric form of flavocytochrome P450 BM3 is catalytically functional as a fatty acid hydroxylase.
Neeli R; Girvan HM; Lawrence A; Warren MJ; Leys D; Scrutton NS; Munro AW
FEBS Lett; 2005 Oct; 579(25):5582-8. PubMed ID: 16214136
[TBL] [Abstract][Full Text] [Related]
10. Laboratory evolution of cytochrome p450 BM-3 monooxygenase for organic cosolvents.
Wong TS; Arnold FH; Schwaneberg U
Biotechnol Bioeng; 2004 Feb; 85(3):351-8. PubMed ID: 14748091
[TBL] [Abstract][Full Text] [Related]
11. Are branched chain fatty acids the natural substrates for P450(BM3)?
Cryle MJ; Espinoza RD; Smith SJ; Matovic NJ; De Voss JJ
Chem Commun (Camb); 2006 Jun; (22):2353-5. PubMed ID: 16733577
[TBL] [Abstract][Full Text] [Related]
12. Regio- and enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3.
Peters MW; Meinhold P; Glieder A; Arnold FH
J Am Chem Soc; 2003 Nov; 125(44):13442-50. PubMed ID: 14583039
[TBL] [Abstract][Full Text] [Related]
13. A single mutation in cytochrome P450 BM3 changes substrate orientation in a catalytic intermediate and the regiospecificity of hydroxylation.
Oliver CF; Modi S; Sutcliffe MJ; Primrose WU; Lian LY; Roberts GC
Biochemistry; 1997 Feb; 36(7):1567-72. PubMed ID: 9048540
[TBL] [Abstract][Full Text] [Related]
14. Evolved CYP102A1 (P450BM3) variants oxidise a range of non-natural substrates and offer new selectivity options.
Whitehouse CJ; Bell SG; Tufton HG; Kenny RJ; Ogilvie LC; Wong LL
Chem Commun (Camb); 2008 Feb; (8):966-8. PubMed ID: 18283351
[TBL] [Abstract][Full Text] [Related]
15. A novel semi-biosynthetic route for artemisinin production using engineered substrate-promiscuous P450(BM3).
Dietrich JA; Yoshikuni Y; Fisher KJ; Woolard FX; Ockey D; McPhee DJ; Renninger NS; Chang MC; Baker D; Keasling JD
ACS Chem Biol; 2009 Apr; 4(4):261-7. PubMed ID: 19271725
[TBL] [Abstract][Full Text] [Related]
16. Use of kinetic isotope effects to delineate the role of phenylalanine 87 in P450(BM-3).
Rock DA; Boitano AE; Wahlstrom JL; Rock DA; Jones JP
Bioorg Chem; 2002 Apr; 30(2):107-18. PubMed ID: 12020135
[TBL] [Abstract][Full Text] [Related]
17. Altering the regioselectivity of cytochrome P450 CYP102A3 of Bacillus subtilis by using a new versatile assay system.
Lentz O; Feenstra A; Habicher T; Hauer B; Schmid RD; Urlacher VB
Chembiochem; 2006 Feb; 7(2):345-50. PubMed ID: 16381045
[TBL] [Abstract][Full Text] [Related]
18. Affinity isolation and characterization of cytochrome P450 102 (BM-3) from barbiturate-induced Bacillus megaterium.
Black SD; Linger MH; Freck LC; Kazemi S; Galbraith JA
Arch Biochem Biophys; 1994 Apr; 310(1):126-33. PubMed ID: 8161195
[TBL] [Abstract][Full Text] [Related]
19. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3.
Kim DH; Kim KH; Kim DH; Liu KH; Jung HC; Pan JG; Yun CH
Drug Metab Dispos; 2008 Nov; 36(11):2166-70. PubMed ID: 18669587
[TBL] [Abstract][Full Text] [Related]
20. Control of the stereo-selectivity of styrene epoxidation by cytochrome P450 BM3 using structure-based mutagenesis.
Huang WC; Cullis PM; Raven EL; Roberts GC
Metallomics; 2011 Apr; 3(4):410-6. PubMed ID: 21240430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
